September 23, 2011 -- China Grand Pharmaceutical and Healthcare Holdings will pay 110 million RMB ($17.2 million) to acquire an 81% stake in Wuhan Kernel Biotechnology. Wuhan Kernel develops and sells bio-pesticides (most of which are exported) and feed additives.China Grand Pharma, headquartered in Hong Kong, makes drugs and APIs in its PRC-based subsidiaries, with a specialty in cardiovascular and ophthalmology drugs. More details....
Stock Symbol: (HK: 0512)
